|
1
|
Thandra KC and Barsouk A, Saginala K,
Aluru JS and Barsouk A: Epidemiology of lung cancer. Contemp Oncol
(Pozn). 25:45–52. 2021.PubMed/NCBI
|
|
2
|
Schad F, Thronicke A, Steele ML, Merkle A,
Matthes B, Grah C and Matthes H: Overall survival of stage IV
non-small cell lung cancer patients treated with Viscum album L. in
addition to chemotherapy, a real-world observational multicenter
analysis. PLoS One. 13:e02030582018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Billing DL and Rimner A: Results of
radiation therapy as local ablative therapy for oligometastatic
non-small cell lung cancer. Cancers (Basel). 13:57732021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wei Y, Cui Y, Guo Y, Li L and Zeng L: A
lung adenocarcinoma patient with a rare EGFR E709_T710delinsD
mutation showed a good response to afatinib treatment: A case
report and literature review. Front Oncol. 11:7003452021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liang H, Li C, Zhao Y, Zhao S, Huang J,
Cai X, Cheng B, Xiong S, Li J, Wang W, et al: Concomitant mutations
in EGFR 19Del/L858R mutation and their association with response to
EGFR-TKIs in NSCLC patients. Cancer Manag Res. 12:8653–8662. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico
TA, et al: Non-small cell lung cancer, version 3.2022, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
20:497–530. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pisano C, De Filippis M, Jacobs F, Novello
S and Reale ML: Management of oligoprogression in patients with
metastatic NSCLC harboring ALK rearrangements. Cancers (Basel).
14:7182022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nguyen KT, Sakthivel G, Milano MT, Qiu H
and Singh DP: Oligoprogression in non-small cell lung cancer: A
narrative review. J Thorac Dis. 14:4998–5011. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shang Y, Li G, Zhang B, Wu Y, Chen Y, Li
C, Zhao W and Liu J: Image-guided percutaneous ablation for lung
malignancies. Front Oncol. 12:10202962022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei Z, Ye X, Yang X, Zheng A, Huang G, Li
W, Wang J, Han X, Meng M and Ni Y: Microwave ablation combined with
EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with
EGFR-sensitive mutations. Oncotarget. 8:56714–56725. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mirsadraee S, Oswal D, Alizadeh Y, Caulo A
and van Beek E Jr: The 7th lung cancer TNM classification and
staging system: Review of the changes and implications. World J
Radiol. 4:128–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feldman AT and Wolfe D: Tissue processing
and hematoxylin and eosin staining. Methods Mol Biol. 1180:31–43.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Magaki S, Hojat SA, Wei B, So A and Yong
WH: An introduction to the performance of immunohistochemistry.
Methods Mol Biol. 1897:289–298. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu J, Zhao R and Zhang J and Zhang J:
ARMS for EGFR mutation analysis of cytologic and corresponding lung
adenocarcinoma histologic specimens. J Cancer Res Clin Oncol.
141:221–227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nan X, Xie C, Yu X and Liu J: EGFR TKI as
first-line treatment for patients with advanced EGFR
mutation-positive non-small-cell lung cancer. Oncotarget.
8:75712–75726. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ramalingam SS, Vansteenkiste J, Planchard
D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y,
Chewaskulyong B, et al: Overall survival with osimertinib in
untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 382:41–50.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim
HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et
al: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung
cancer. N Engl J Med. 376:629–640. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa
K, Niho S, Lee M, Linke R, Rosell R, Corral J, et al: Improvement
in overall survival in a randomized study that compared dacomitinib
with gefitinib in patients with advanced non-small-cell lung cancer
and EGFR-activating mutations. J Clin Oncol. 36:2244–2250. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY,
Cui JW, Yang N, Song Y, Li XL, Lu S, et al: Bevacizumab plus
erlotinib in Chinese patients with untreated, EGFR-mutated,
advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Cancer Cell. 39:1279–1291.e3. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu Q, Luo W, Li W, Wang T, Huang L and Xu
F: First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI
alone as first-line treatment in advanced NSCLC with EGFR
activating mutation: A systematic review and meta-analysis of
randomized controlled trials. Front Oncol. 11:5982652021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chinese Society of Clinical Oncology, .
Guidelines of Chinese Society of Clinical Oncology (CSCO) Primary
Lung Cancer 2016.V1. People's Medical Publishing House, Beijing,
China. https://meeting.csco.org.cn/pdf/web/viewer.html?file=/upload/Periodical/201811/201811965213.pdfAccessed
November 9, 2018 (In Chinese).
|
|
22
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xia GH, Zeng Y, Fang Y, Yu SR, Wang L, Shi
MQ, Sun WL, Huang XE, Chen J and Feng JF: Effect of EGFR-TKI
retreatment following chemotherapy for advanced non-small cell lung
cancer patients who underwent EGFR-TKI. Cancer Biol Med.
11:270–726. 2014.PubMed/NCBI
|
|
24
|
Lin M, Eiken P and Blackmon S: Image
guided thermal ablation in lung cancer treatment. J Thorac Dis.
12:7039–7047. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vogt A, Schmid S, Heinimann K, Frick H,
Herrmann C, Cerny T and Omlin A: Multiple primary tumours:
Challenges and approaches, a review. ESMO Open. 2:e0001722017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pan SY, Huang CP and Chen WC:
Synchronous/metachronous multiple primary malignancies: Review of
associated risk factors. Diagnostics (Basel). 12:19402022.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gonzalez-Tallon AI, Vasquez-Guerrero J and
Garcia-Mayor MA: Colonic metastases from lung carcinoma: A case
report and review of the literature. Gastroenterology Res. 6:29–33.
2013.PubMed/NCBI
|
